This indicated that allo-HSCT could not triumph over the adverse prognostic effect of them, which were consistent with previous research results that FLT3-ITD, TP53, and RUNX1 mutations conferred a poor prognosis on AML even after allo-HSCT [11–13]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.